Trials / Active Not Recruiting
Active Not RecruitingNCT05621317
A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- Sponsor
- Aravax Pty Ltd · Industry
- Sex
- All
- Age
- 4 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
The overall aims of this study are to demonstrate that treatment with PVX108 immunotherapy has an acceptable safety profile and is effective for reducing clinical reactivity to peanut protein in children and adolescents with peanut allergy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | PVX-108 | PVX108 comprises a mixture of peptides that represent sequences from peanut allergens |
| BIOLOGICAL | Placebo | Matching placebo comprises the formulation vehicle without peptides |
Timeline
- Start date
- 2023-02-09
- Primary completion
- 2025-11-01
- Completion
- 2027-06-01
- First posted
- 2022-11-18
- Last updated
- 2025-10-15
Locations
14 sites across 2 countries: United States, Australia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05621317. Inclusion in this directory is not an endorsement.